22:35 , Jul 11, 2019 |  BC Innovations  |  Emerging Company Profile

Twentyeight-Seven’s bet on RNA-binding proteins

Twentyeight-Seven is building a small molecule platform to target interactions between non-coding RNAs and an emerging target class in gene regulation: RNA-binding proteins. Launched last September, the company is using an $82.8 million series A...
19:52 , Jun 28, 2018 |  BC Innovations  |  Emerging Company Profile

Stress relief for neurons

Aquinnah Pharmaceuticals is developing disease-modifying therapies for amyotrophic lateral sclerosis and Alzheimer’s disease by inhibiting the formation of stress granules that promote protein aggregation in neurons. Stress granules are protein-RNA complexes assembled by RNA-binding proteins...
15:32 , Jun 8, 2018 |  BioCentury  |  Finance

Pfizer plugs back in

While Pfizer Inc. (NYSE:PFE) retreated from neuroscience R&D in January, the pharma hasn’t cut the cord yet. Ramped up allocations to neuroscience out of its latest $600 million venture investment give Pfizer the ability to...
15:17 , Jun 8, 2018 |  BC Week In Review  |  Financial News

Pfizer allocates $600M to venture, with neuroscience a focus

Pfizer Inc. (NYSE:PFE) on June 6 said it will invest $600 million in biotech and other emerging growth companies via Pfizer Ventures, with about $150 million devoted to early stage neuroscience companies. Pfizer said initial...
12:01 , Jun 6, 2018 |  BC Extra  |  Financial News

Pfizer allocates $600M to venture, with neuroscience a focus

Pfizer Inc. (NYSE:PFE) said it will invest $600 million in biotech and other emerging growth companies via Pfizer Ventures, with about $150 million devoted to early stage neuroscience companies. Pfizer said initial areas of interest...
21:10 , Apr 27, 2017 |  BC Week In Review  |  Financial News

Aquinnah completes venture round

On April 25, neurodegenerative disease company Aquinnah Pharmaceuticals (Cambridge, Mass) raised $10 million in a venture round from new investors Pfizer Inc. and AbbVie Inc. Aquinnah Pharmaceuticals , Cambridge, Mass. ...
08:00 , Jan 4, 2016 |  BC Week In Review  |  Financial News

Aquinnah Pharmaceuticals completes venture financing

Aquinnah Pharmaceuticals , Cambridge, Mass.   Business: Neurology   Date completed: 2015-12-21   Type: Venture financing   Raised: $5 million   Investor: Takeda Pharmaceutical Co. Ltd.  ...
01:49 , Dec 22, 2015 |  BC Extra  |  Financial News

Takeda invests $5M in Aquinnah

Aquinnah Pharmaceuticals (Cambridge, Mass.) said Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) invested $5 million in the newco's first equity round. Aquinnah said it is developing therapies that target pathological protein complexes in the brains of most...